
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing

- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows